The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.

Also, it is known that if taken for weight loss, the drug will likely be taken for life. Malhotra said research is still out on whether the same goes for treating sleep apnea.

And as of December 20, Eli Lilly's weight loss drug Zepbound (tirzepetide) has become the first prescription medication FDA-approved to treat obstructive sleep apnea by increasing airflow and ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

And as of December 20, Eli Lilly’s weight loss drug Zepbound (tirzepetide) has become the first prescription medication FDA-approved to treat obstructive sleep apnea by increasing airflow and ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The U.S. Food and Drug Administration has approved the weight-loss drug Zepbound to treat obstructive sleep apnea, it announced Friday. Zepbound is the first drug for the condition to receive ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.